Clinical Trial Update: Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial (NCT02223208) evaluates Ro plus CHOEP as first-line therapy before hematopoietic stem cell transplantation in young patients with nod…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Lymphoma Kinase-negative Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Nodal Peripheral T-cell Lymphoma with Follicular Helper Cell Phenotype
• Peripheral T-cell Lymphoma
• Peripheral T-cell Lymphoma Not Otherwise Specified

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Etoposide (Etoposide)
• Vincristine (vincristine)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Peripheral T-cell Lymphomas (PTCL), PTCL-NOS | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING